Briacell Therapeutics CorpNASDAQ:BCTXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)View on Canadian Exchange
- LAST PRICE0.5612
- TODAY'S CHANGE (%)-0.0338 (-5.6807%)
- Bid / Lots0.5612/ 10
- Ask / Lots0.5698/ 6
- Open / Previous Close0.5884 / 0.5950
- Day Range
- 52 Week Range
- Volume224,333
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BCTX |
|---|---|---|
| 09:32 ET | 15616 | 0.58 |
| 09:33 ET | 9967 | 0.585 |
| 09:35 ET | 250 | 0.585 |
| 09:37 ET | 3999 | 0.573 |
| 09:42 ET | 800 | 0.581126 |
| 09:44 ET | 500 | 0.575 |
| 09:46 ET | 1000 | 0.575 |
| 09:48 ET | 100 | 0.575 |
| 09:50 ET | 22900 | 0.5688 |
| 09:55 ET | 500 | 0.5688 |
| 09:57 ET | 400 | 0.57 |
| 10:06 ET | 2276 | 0.5702 |
| 10:08 ET | 100 | 0.5702 |
| 10:09 ET | 4000 | 0.571859 |
| 10:11 ET | 500 | 0.57 |
| 10:13 ET | 10440 | 0.565 |
| 10:15 ET | 5730 | 0.5649 |
| 10:18 ET | 25578 | 0.5602 |
| 10:20 ET | 3331 | 0.5626 |
| 10:22 ET | 6000 | 0.565 |
| 10:24 ET | 485 | 0.5588 |
| 10:26 ET | 500 | 0.5609 |
| 10:27 ET | 550 | 0.5573 |
| 10:29 ET | 7100 | 0.5573 |
| 10:31 ET | 19994 | 0.5605 |
| 10:33 ET | 12605 | 0.555 |
| 10:36 ET | 1750 | 0.5615 |
| 10:38 ET | 5000 | 0.5615 |
| 10:40 ET | 1305 | 0.560001 |
| 10:42 ET | 8815 | 0.563 |
| 10:44 ET | 885 | 0.5634 |
| 10:49 ET | 1000 | 0.5601 |
| 10:51 ET | 19719 | 0.555 |
| 10:54 ET | 285 | 0.5592 |
| 10:58 ET | 2400 | 0.562393 |
| 11:00 ET | 350 | 0.56 |
| 11:03 ET | 2000 | 0.5633 |
| 11:05 ET | 1017 | 0.56 |
| 11:14 ET | 2000 | 0.5612 |
| 11:16 ET | 100 | 0.5612 |
| 11:18 ET | 9396 | 0.5656 |
| 11:20 ET | 300 | 0.563 |
| 11:21 ET | 368 | 0.567752 |
| 11:27 ET | 380 | 0.5612 |
| 11:30 ET | 100 | 0.5612 |
Nov 8, 2024
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference, from 7:50AM ET on Friday Nov 08, 2024 by Dow Jones
7:50AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 4, 2024
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium(R), December 10 -- 13, from 7:50AM ET on Monday Nov 04, 2024 by Dow Jones
7:50AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 22, 2024
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data, from 7:50AM ET on Tuesday Oct 22, 2024 by Dow Jones
7:50AM ET on Tuesday Oct 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Briacell Therapeutics Corp | 29.4M | 0.0x | --- |
Company Information
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Contact Information
- Headquarters
- Suite 300 - Bellevue Centre 235 -15th StreetWEST VANCOUVER, BC, Canada V7T 2X1
- Phone
- 604-921-1810
- Fax
- 604-921-1898
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $29.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.80 |
EPS | $-0.43 |
Book Value | $-0.18 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
